BMS-833923 clinical trials
Also written BMS-833923 and XL139.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2008
How each study uses BMS-833923 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2009 (2)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 2 |
| 2014 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 1
Bristol-Myers Squibb (6) · University Health Network, Toronto (1)
Studies
Open first, then newest update. How each study uses BMS-833923 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Study of BMS-833923 in Two Specific Patients With Basal Cell Nevus SyndromeCompletedNot applicableUniversity Health Network, TorontoNCT02100371Written as BMS-833923
- Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)TerminatedPhase 2Bristol-Myers SquibbNCT01357655Written as BMS-833923
- Multiple Ascending Dose (MAD) Combination in Subjects With Multiple MyelomaCompletedPhase 1Bristol-Myers SquibbNCT00884546Written as BMS-833923
- A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic CancerCompletedPhase 1Bristol-Myers SquibbNCT00670189Written as BMS-833923 (XL139)
- A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal AdenocarcinomasCompletedPhase 1Bristol-Myers SquibbNCT00909402Written as BMS-833923
- Phase 1 Multiple Ascending Dose Study of BMS-833923 (XL139) in Subjects With Solid TumorsCompletedPhase 1Bristol-Myers SquibbNCT01413906Written as BMS-833923 (XL139)
- A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung CancerCompletedPhase 1Bristol-Myers SquibbNCT00927875Written as BMS-833923
Given beside what is tested · 1 — BMS-833923 is usual care or a partner of the new treatment
Codes
What other systems call BMS-833923 · ClinicalTrials.gg INT006336
- Wikidata Q27075373BMS-833923One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| Wikidata | Q27075373 | BMS-833923 | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.